Pfizer closes Array acquisition
NEW YORK and BOULDER — Pfizer Inc. (NYSE: PFE) has completed its $11 billion acquisition of Boulder-based oncology company Array BioPharma.
Approximately 77 percent of Array shares were tendered to Pfizer by the deadline last Friday, according to filings with the U.S. Securities and Exchange Commission, meeting the deal’s minimum requirements. Array’s stock, which was purchased at $48 per share by Pfizer, was delisted from the Nasdaq exchange at $47.85 per share Tuesday morning.
Array and Pfizer announced the deal on June 17.
“We are proud to bring Array’s exceptional…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
BOULDER — Even with the COVID-10 pandemic several years in the rearview mirror, it remains…
-
LOVELAND — The Stinging Nettle has taken up residence in downtown, filling a hole recently…
-
Boulder Community Health this month became the first facility in Colorado to offer patients a…
-
Nextera Healthcare LLC and ImagineMD have combined to form a single direct-primary-care organization for employer…
